These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 37435402)

  • 1. Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.
    Phan AN; Terry GE
    Front Psychiatry; 2023; 14():1144276. PubMed ID: 37435402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The psychedelic effects of cannabis: A review of the literature.
    Wolinsky D; Barrett FS; Vandrey R
    J Psychopharmacol; 2024 Jan; 38(1):49-55. PubMed ID: 37947321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of psychedelics in the Czech Republic: results of recent population surveys.
    Chomynová P; Kočárová R; Kňažek F; Plevková M; Bláhová B; Valeš K; Mravčík V
    Cent Eur J Public Health; 2022 Sep; 30(3):144-153. PubMed ID: 36239361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.
    Jones GM; Nock MK
    Sci Rep; 2022 Feb; 12(1):2574. PubMed ID: 35173246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing Cannabis Use in Young Adults With Psychosis Using iCanChange, a Mobile Health App: Protocol for a Pilot Randomized Controlled Trial (ReCAP-iCC).
    Tatar O; Abdel-Baki A; Wittevrongel A; Lecomte T; Copeland J; Lachance-Touchette P; Coronado-Montoya S; Côté J; Crockford D; Dubreucq S; L'Heureux S; Ouellet-Plamondon C; Roy MA; Tibbo PG; Villeneuve M; Jutras-Aswad D
    JMIR Res Protoc; 2022 Nov; 11(11):e40817. PubMed ID: 36427227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
    Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA
    Psychopharmacology (Berl); 2022 Jan; 239(1):15-33. PubMed ID: 34812901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder.
    Velit-Salazar MR; Shiroma PR; Cherian E
    Brain Sci; 2024 Mar; 14(3):. PubMed ID: 38539636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
    Bender D; Hellerstein DJ
    Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review.
    Gorelick DA
    Curr Pharm Des; 2016; 22(42):6409-6419. PubMed ID: 27549375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
    Andrews CM; Hall W; Humphreys K; Marsden J
    Addiction; 2024 Jun; ():. PubMed ID: 38845381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials.
    Vuilleumier C; Scherbaum N; Bonnet U; Roser P
    Front Psychiatry; 2022; 13():867878. PubMed ID: 35815028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Role of Serotonergic Hallucinogens in Depression Treatment.
    Psiuk D; Nowak E; Cholewa K; Łopuszańska U; Samardakiewicz M
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
    Johnston CB; Mangini M; Grob C; Anderson B
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):44-53. PubMed ID: 36184377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.